GL1X · GenesisL1 explorer

Research workbench

Structure of penicillin-binding protein 5 from E.COLI: cefoxitin acyl- enzyme complex

Analyse Structure of penicillin-binding protein 5 from E.COLI: cefoxitin acyl- enzyme… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3MZE
Type
protein
Length
352 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
D-alanyl-D-alanine carboxypeptidase daca
EC
3.4.16.4, 3.5.2.6
UniProt
P0AEB2
Ligands
1QL
Pockets
3 · best druggability 0.44

Structure

x-ray diffraction · 1 distinct chain · 31% helix, 33% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AD-alanyl-D-alanine carboxypeptidase daca (EC 3.4.16.4, 3.5.2.6)protein35231% helix, 33% strandP0AEB2

Ligands and binding sites

  • 1QL · (2R)-5-[(carbamoyloxy)methyl]-2-{(1S)-1-methoxy-2-oxo-1-[(thiophen-2-ylacetyl)amino]ethyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid · ligand · chains A
  • GOL · Glycerol · additive · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11540.440.75271QL
21270.410.7518empty
3590.280.7414GOL

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 3MZE · Structure of penicillin-binding protein 5 from E.coli: cefoxitin acyl-enzyme complex · the same entry in another collection · chain A against A, TM-score 1.00
  • P0AEB2 · AlphaFold monomer V2.0 prediction for D-alanyl-D-alanine carboxypeptidase daca (P0AEB2) · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.